Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies

Kasmas, S.H.; Izar, M.C.; França, C.N.; Ramos, S.C.; Moreira, F.T.; Helfenstein, T.; Moreno, R.A.; Borges, N.C.; Figueiredo-Neto, A.M.; Fonseca, F.A..
Braz. j. med. biol. res ; 45(11): 1095-1101, Nov. 2012. ilus, tab
Artigo em Inglês | LILACS | ID: lil-650576

Similares

  1. PCSK9 Inhibitors.
  2. IMPROVE-IT: what have we learned?
  3. Efficacy and safety of different doses of alirocumab in reducing low-density lipoprotein cholesterol levels: a network meta-analysis.
  4. Evinacumab in Patients with Refractory Hypercholesterolemia.
  5. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials.
  6. Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies.
  7. [Ezetimibe-rosuvastatin fixed-dose combination (Myrosor®)].
  8. [IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].
  9. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
  10. Lipids, inflammation, and chronic kidney disease: a SHARP perspective.